SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2026)

SAB Biotherapeutics has reported Non Operating Income for 6 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 79.75% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $57.8 million (up 620.85% YoY), and the FY2025 full-year result was $62.2 million, up 606.71% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.1 million, up from -$1.1 million in the prior quarter.
• The five-year high for Non Operating Income was $58.1 million in Q3 2025, with the low at -$4.0 million in Q4 2023.
• Historically, Non Operating Income has averaged $4.6 million across 5 years, with a median of $731248.0 in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income plunged 36168.02% — and 2024, when it surged 13108.14%.
• SAB Biotherapeutics' Non Operating Income stood at $11043.0 in 2022, then sank by 36168.02% to -$4.0 million in 2023, then jumped by 65.21% to -$1.4 million in 2024, then increased by 21.31% to -$1.1 million in 2025, then surged by 203.52% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), -$1.1 million (Q4 2025), and $58.1 million (Q3 2025), per Business Quant data.